- Home
- GLUE vs SIFY Comparison
GLUE vs SIFY Comparison
Compare GLUE & SIFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | SIFY |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | GLUE | SIFY |
|---|---|---|
| Price | $21.17 | $14.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 103.6K |
| Earning Date | 03-19-2026 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | $181,538,000.00 | ★ $473,538,214.00 |
| Revenue This Year | $84.02 | N/A |
| Revenue Next Year | N/A | $13.07 |
| P/E Ratio | $91.51 | ★ N/A |
| Revenue Growth | ★ 1112.27 | 6.85 |
| 52 Week Low | $3.50 | $2.92 |
| 52 Week High | $25.77 | $17.85 |
Technical Indicators
Market Signals| Indicator | GLUE | SIFY |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 56.29 |
| Support Level | $22.05 | $13.21 |
| Resistance Level | $23.29 | $15.85 |
| Average True Range (ATR) | 1.44 | 1.35 |
| MACD | -0.34 | -0.02 |
| Stochastic Oscillator | 1.29 | 59.83 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About SIFY Sify Technologies Limited
Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.